Serum Institute gets DCGI nod to resume Covid-19 vaccine
New Delhi/IBNS: The Serum Institute of India (SII) has got the nod of the Drug Controller General of India (DCGI) to resume the phase two and three trials for Covid-19 vaccine, media reports said.
The SII had reportedly sought permission from the DCGI to resume trials for the vaccine developed by pharmaceutical giant AstraZeneca and Oxford University.
The Oxford vaccine trial was first halted by AstraZeneca after a suspected serious adverse reaction was seen in a participant in the United Kingdom last week.
Following the development, the SII had also halted the vaccine trials in the country, but of course after being pulled up by the DCGI.
The central drug regulator had pulled up the SII for not informing it about the pause of vaccine trials in other nations.
AstraZeneca last Saturday resumed the trials for the vaccine.